Latest News by Industry
DUBLIN--(BUSINESS WIRE)--Sep 21, 2022--
The "Recombinant Proteins Market Size, Share & Trends Analysis Report by Host Cell (Insect Cells, Mammalian), by Application (Research, Therapeutics), by Product & Services, by End-user, by Region, and Segment Forecasts, 2022-2030" report has been added to ResearchAndMarkets.com's offering.
The global recombinant proteins market size is expected to reach USD 5.09 billion by 2030, registering a CAGR of 12.0% over the forecast period, according to this report.
Companies Mentioned
Diseases like multiple sclerosis, neutropenia, cerebral apoplexy, anemia, and others, as well as dwarfism, are becoming more common, which is driving up the demand for recombinant protein drugs. Furthermore, the industry is anticipated to expand due to the increased development and research on biologics, which, in turn, are significantly boosting global industry growth. The focus on the development of biosimilars, biologics, and recombinant proteins has increased owing to a rise in the incidence and prevalence of cancer and the expansion of research & development activity.
According to the American Cancer Society, in 2022, there will be 1.9 million new cases of cancer and 609,360 cancer-related deaths. In addition, the expanding application of recombinant proteins in clinical diagnostic methods including ELISA, Western Blotting, and Immunohistochemistry (IHC) is anticipated to fuel market expansion.
Due to factors including rising R&D spending, an increase in the number of cancer patients, and the desire for novel & tailored therapies, the global industry is anticipated to expand significantly during the forecast period. Research activity in recombinant protein space has increased in response to the COVID-19 pandemic as a result of efforts to comprehend the dynamics of the virus. The production of recombinant proteins has increased significantly, along with tailored treatment.
In addition, research funding is predicted to become more readily available along with an increase in demand for and production of recombinant proteins, particularly those immune response proteins associated with COVID-19. Therefore, positive effects have been seen for the companies offering products specifically made for COVID-19.
Recombinant protein is viewed as a modified version of natural protein that can be produced in a number of ways to improve protein output, create useful commercial goods, and alter gene sequences. The rise in pharmaceutical firms' R&D expenditures, high incidence of chronic illnesses, an increase in the number of regulatory requirements, and the ongoing need to reduce viral infections are the main drivers of the global industry.
Recombinant Proteins Market Report Highlights
Key Topics Covered:
Chapter 1 Research Methodology
Chapter 2 Executive Summary
Chapter 3 Market Variables, Trends & Scope
3.1 Market Trends & Outlook
3.2 Market Segmentation And Scope
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Growing Research Activities For Drug Development And Precision Medicine
3.3.1.2 Rising Adoption Of Biologics And Biosimilars
3.3.1.3 Increasing Investments In Research & Development Activities
3.3.2 Market Restraint Analysis
3.3.2.1 Regulatory And Safety Concerns With Protein Production
3.3.2.2 Dearth Of Skilled Personnel And Expertise
3.3.3 Market Opportunity Analysis
3.3.3.1 Declining Cost Of Therapeutics Recombinant Proteins And Advent Of Biosimilars
3.3.3.2 Innovative Techniques Can Decrease The Recombinant Protein Production Cost
3.4 Business Environment Analysis Tools
3.4.1 Swot Analysis, By Pest
3.4.2 Porter's Five Forces Analysis
3.5 Penetration & Growth Prospect Mapping For Product, 2021
3.6 Recombinant Proteins Market: Covid-19 Impact Analysis
Chapter 4 Product Segment Analysis
Chapter 5 Application Segment Analysis
Chapter 6 End-User Segment Analysis
Chapter 7 Host-Cells Segment Analysis
Chapter 8 Regional Outlook
Chapter 9 Competitive Landscape
9.1 Strategy Framework
9.2 Market Participation Categorization
9.3 Company Profiles
For more information about this report visit https://www.researchandmarkets.com/r/2fs4zc
View source version on businesswire.com:https://www.businesswire.com/news/home/20220921005644/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: BIOTECHNOLOGY GENETICS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2022.
PUB: 09/21/2022 08:16 AM/DISC: 09/21/2022 08:17 AM
http://www.businesswire.com/news/home/20220921005644/en